Heart attack drug trial halted: could quick cholesterol drop save hearts?

NCT ID NCT05613426

Terminated Disease control Sponsor: Henan Institute of Cardiovascular Epidemiology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving a powerful cholesterol-lowering drug (evolocumab) very early after a major heart attack could help the heart pump better and prevent long-term damage. About 119 adults who were having a heart attack and scheduled for a procedure to open blocked arteries took part. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction Ventricular Remodeling

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ST-ELEVATION MYOCARDIAL INFARCTION (STEMI)

Contacts and locations

Locations

Fuwai Central China Cardiovascular Hospital

Zhengzhou, Henan, China
Hopeshine Minsheng Hospital of Xinzheng

Xinzheng, Henan, China
Kaifeng Central Hospital

Kaifeng, Henan, China
The People's Hospital of Changyuan

Xinxiang, Henan, China
The People's Hospital of Gongyi

Gongyi, Henan, China
The People's Hospital of Xuchang

Xuchang, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.